Conduct of Study; Suspension Sample Clauses

Conduct of Study; Suspension. Institution agrees to administer, and Investigator agrees to conduct, this Study solely at the Institution. The Institution may not be changed without Sponsor’s prior written consent. The Study shall commence as soon as possible following receipt of EC and local Regulatory Authority written approval, or as otherwise agreed upon in writing with Sponsor. Sponsor plans to conduct the Study at multiple sites, including at the Institution. Sponsor or CRO may suspend the entire Study (or a portion of the Study conducted by Investigator at Institution) at any time for any reason. Institution or Investigator may suspend the portion of the Study conducted by Institution and Investigator at Institution, if, using reasonable and good medical judgment consistent with generally accepted standards of care, Investigator or Institution reasonably determine it is appropriate to do so to protect the health or safety of the subject participating in the Study and immediately provide written notice thereof to Sponsor and CRO. The suspension of the Study by Sponsor, CRO, Institution or Investigator in accordance with this Section 1.3 shall not be deemed a material breach of this Agreement. The Institution shall notify the Sponsor promptly if the Investigator is unable or unwilling to continue the Study or if the Investigator’s affiliation with the Institution ceases, whereupon the Sponsor will have a right of approval with respect to the designation of a new investigator. Provádění studie; Zastavení. Poskytovatel zdravotních služeb a Zkoušející souhlasí s tím, že tato Studie bude prováděna výlučně ve Zdravotnickém zařízení. Poskytovatel zdravotních služeb nesmí být změněn bez předchozího písemného souhlasu Zadavatele. Studie bude zahájena co možná nejdříve po přijetí písemného schválení EK a lokálním Regulačním orgánem nebo jinak podle toho, jak bude schváleno písemně Zadavatelem. Zadavatel plánuje provést Studii na více centrech, včetně Poskytovatele zdravotních služeb. Zadavatel nebo CRO může kdykoli a z jakéhokoli důvodu ukončit celou Studii (nebo část Studie prováděnou Zkoušejícím ve Zdravotnickém zařízení). Poskytovatel zdravotních služeb nebo Zkoušející mohou zastavit část Studie prováděné Zdravotnickým zařízením a Zkoušejícím ve Zdravotnickém zařízení, pokud s použitím přiměřeného a dobrého lékařského úsudku odpovídajícího obecně přijímaným standardům péče Zkoušející nebo Poskytovatel zdravotních služeb rozumně stanoví, že je to vhodné pro ochranu zdraví nebo bezpečnosti...
Sample 1See All (4)
AutoNDA by SimpleDocs
Conduct of Study; Suspension. Institution agrees and ensures that Investigator agrees to administer this Study solely at the Institution and at other subcontracted locations only after Sponsor’s approval (if applicable). The Institution may not be changed without Sponsor’s prior written consent. The Study shall commence as soon as possible following receipt of RA and ECs written approval, or as otherwise agreed upon in writing with Sponsor. Sponsor plans to conduct the Study at multiple sites, including the Institution. Sponsor or CRO may suspend the entire Study (or the portion of the Study conducted by Institution) at any time for any reason. Institution may suspend the portion of the Study conducted by Institution, if, using good medical judgment, Institution or assigned Investigator determine it is appropriate to do so for the medical benefit of the subject participating in the Study. The suspension of the Study by Xxxxxxx, CRO, or Institution in accordance with this Section 1.4 shall not be deemed a material breach of this Agreement.
Sample 1
Conduct of Study; Suspension. Institution agrees to administer, and Investigator agrees to conduct, this Study solely at the Institution. The Institution may not be changed without Sponsor’s prior written consent. The Study shall commence as soon as possible following receipt of EC and local Regulatory Authority written approval, or as otherwise agreed upon in writing with Sponsor. Sponsor plans to conduct the Study at multiple sites, including at the Institution. Sponsor or CRO may suspend the entire Study (or a portion of the 1.3
Sample 1
Conduct of Study; Suspension. Provider agrees to administer, and Investigator agrees to conduct, this Study solely at the Provider. The Provider may not be changed without GWWO’s prior written consent. The 1.3
Sample 1

Related to Conduct of Study; Suspension

  • Conduct of the Study The Parties shall perform the Study set forth in Protocol No. [ ] dated [ ] (“Protocol”) in accordance with this Agreement, the Protocol and all applicable laws and regulations. The Institution shall follow all guidelines and instructions reasonably provided by Sponsor. [If applicable:] The Principal Investigator has, in addition to his/her Principal Investigator responsibilities, been appointed to coordinate certain activities at a national level as National Coordinating Investigator. It is the duty of the National Coordinating Investigator to obtain all approvals for the Study required pursuant to Norwegian law or regulatory requirements from the relevant Independent Ethics Committee (“IEC”) before commencing the Study. The National Coordinating Investigator shall also, to the extent required pursuant to Norwegian law or regulatory requirements, notify and obtain the consent of the relevant EC of any amendments to the Protocol. Such approvals shall be forwarded to Sponsor as they are obtained.

  • Conduct of Hearing a. The formal rules of evidence do not apply, although the presiding officer will have discretion to exclude evidence that is incompetent, irrelevant, or cumulative, or the presentation of which will otherwise consume undue time.

  • Inspection and Approval All works embracing more than one process shall be subject to examination and approval at each stage thereof and the Contractor shall given due notice to the Engineer-in-Charge or his authorized representative when each stage is ready. In default of such notice the Engineer-in- Charge shall be entitled to appraise the quality and extent thereof.

  • Application and Approval (a) 1. An employee shall make written application to her Employer on or before January 31st of the year in which the deferment is to commence, requesting permission to participate in the Plan.

  • Conduct of Logging Unless otherwise specifi- cally provided herein, Purchaser shall fell trees desig- nated for cutting and shall remove the portions that meet Utilization Standards, as provided in B2.2, prior to accep- tance of subdivision for completion of logging under B6.36. Forest Service may make exceptions for occa- sional trees inadvertently not cut or trees or pieces not removed for good reason, including possible damage to forest resources or gross economic impracticability at the time of removal of other timber. Logging shall be con- ducted in accordance with the following, unless C6.4 pro- visions set forth requirements to meet special or unusual logging conditions:

  • Effect of Suspension You must pay all applicable fees incurred before and during any suspension. You will not be entitled to any service credits under an applicable Service Level Agreement or Service Level Objective during any suspension.

  • Submission and Approval The Contractor’s Submittals must comply with the Contract Documents. The Contractor shall review and approve all Submittals prior to submission. The Contract Documents shall specify when shop drawings or submittals require the seal of a specialty consultant. The Contractor shall submit copies of Submittals as required by the Contract Documents for the Work of the various trades. The Design Professional shall review, approve, or take other appropriate action with respect to shop drawings, samples, or other submissions of the Contractor, including, but not limited to, confirming conformance with the design concept of the Project and with the Contract Documents. The Design Professional shall respond to and return said items to the Contractor within fourteen calendar days from receipt provided that the Submittals are submitted by the Contractor in accordance with the required Submittal schedule. The Design Professional shall review and give comment or approval to Submittal schedule within fourteen calendar days from receipt. Large submittal documents may require longer review times, e.g., submittals with over fifty sheets of drawings. If, because of events beyond its reasonable control, the Design Professional is not able to meet the specified time period, then it is entitled to ask for additional time from the Owner. The Contractor shall make all corrections required by the Design Professional and furnish such corrected copies as may be needed. If the Contractor believes that any corrections required by the Design Professional constitute a change to the contract, the Contractor shall immediately notify the Design Professional and Owner and request instructions. By forwarding the approved Submittals to the Design Professional, the Contractor represents that the Contractor has determined and verified materials, field measurements, and field construction criteria related thereto, or will do so, and has checked and coordinated the information contained within such Submittals with the requirements of the Work and of the Contract Documents. The Design Professional’s approval of Submittals shall not relieve the Contractor from the responsibility for errors of any sort in Submittals or schedules. The Contractor shall perform no portion of the Work for which the Contract Documents require Submittals until the Design Professional has approved the respective Submittal. The Contractor shall maintain at the Site one copy of all approved Submittals.

  • Conduct of Hearings Hearings shall be conducted in accordance with the procedures contained in Government Code Section 11513. Hearing sessions shall be private with attendance limited to the panel, the parties’ representatives and witnesses as scheduled. In cases involving below-standard evaluations or disciplinary action, the District shall proceed first in providing evidence.

  • Project Suspension 6.3.1 If the project is suspended for the convenience of the Owner for more than three months or terminated in whole or in part, during any Phase, the Project Consultant shall be paid for services authorized by an Authorization To Proceed which were performed prior to such suspension or termination, together with the cost of Reimbursable Services and expenses then due.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.